Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Biota Receives $4.2m R&D Tax Credit


Biota Receives $4.2m R&D Tax Credit

MELBOURNE, AUSTRALIA -- (Marketwire) -- 11/07/12 -- In addition to the disclosure in the 2012 Annual Report, Biota Holdings limited (ASX: BTA) today announced that it received $4.2m in respect to the Australian Research and Development tax incentive ("Offset "), following submission of its 2012 Australian tax return.

As a result, Biota's cash position increased by $4.2m and will be recognized as a tax credit in the income statement in the December quarter financial reports.

About Biota Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has a well advanced program for human rhinovirus (HRV) infection with a completed Phase IIb study in asthmatic subjects.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza antivirals, of which the lead product lnavir(R), is marketed in Japan. Biota holds a contract from the US Office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of laninamivir in the USA.

Relenza(TM) is a registered trademark of the GlaxoSmithKline group of companies. Inavir(R) is registered to Daiichi Sankyo.

Investor / Analyst Inquiries Biota Holdings Limited Peter Cook T: +61 3 9915 3720 Damian Lismore T: +61 3 9915 3721

Media Inquiries Nerida Mossop Hinton & Associates T: +61 3 9600 1979 / M: +61 437 361 433 Felicity Williams Hinton & Associates T: +61 3 9600 1979 / M: +61 416 770 012

US Inquiries Hershel Berry Blueprint Life Science Group M: +1 415 505 3749

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement